VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling. by Passemard, Sandrine (author) et al.
Research article
3072	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 121	 	 	 Number 8	 	 	 August 2011
VIP blockade leads to microcephaly in mice 
via disruption of Mcph1-Chk1 signaling
Sandrine Passemard,1,2,3,4 Vincent El Ghouzzi,1,2 Hala Nasser,1,2 Catherine Verney,1,2  
Guilan Vodjdani,5 Adrien Lacaud,6,7 Sophie Lebon,1,2 Marc Laburthe,2,8 Patrick Robberecht,9 
Jeannette Nardelli,1,2 Shyamala Mani,10 Alain Verloes,1,2,4  
Pierre Gressens,1,2,3,11 and Vincent Lelièvre1,2,6,7
1Inserm, U676, Paris, France. 2Université Paris 7, Faculté de Médecine Denis Diderot, Paris, France. 3Assistance Publique Hôpitaux de Paris (AP HP),  
Hôpital Robert Debré, Service de Neurologie Pédiatrique, and 4AP HP, Hôpital Robert Debré, Service de Génétique Clinique, Paris, France.  
5Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, CNRS UMR-7225, Inserm UMR-975, Université Pierre et Marie Curie,  
Paris, France. 6CNRS, UPR 3212, Strasbourg, France. 7Université de Strasbourg, Strasbourg, France. 8Inserm, U773, Paris, France.  
9Laboratory of Biological Chemistry and Nutrition, Université Libre de Bruxelles, Brussels, Belgium. 10Center for Neuroscience,  
Indian Institute of Science, Bangalore, India. 11Centre for the Developing Brain, Imperial College,  
Hammersmith Campus, London, United Kingdom.
Autosomal	recessive	primary	microcephaly	(MCPH)	is	a	genetic	disorder	that	causes	a	reduction	of	cortical	out-
growth	without	severe	interference	with	cortical	patterning.	It	is	associated	with	mutations	in	a	number	of	genes	
encoding	protein	involved	in	mitotic	spindle	formation	and	centrosomal	activities	or	cell	cycle	control.	We	
have	shown	previously	that	blocking	vasoactive	intestinal	peptide	(VIP)	during	gestation	in	mice	by	using	a	VIP	
antagonist	(VA)	results	in	microcephaly.	Here,	we	have	shown	that	the	cortical	abnormalities	caused	by	prenatal	
VA	administration	mimic	the	phenotype	described	in	MCPH	patients	and	that	VIP	blockade	during	neurogen-
esis	specifically	disrupts	Mcph1	signaling.	VA	administration	reduced	neuroepithelial	progenitor	proliferation	
by	increasing	cell	cycle	length	and	promoting	cell	cycle	exit	and	premature	neuronal	differentiation.	Quantita-
tive	RT-PCR	and	Western	blot	showed	that	VA	downregulated	Mcph1.	Inhibition	of	Mcph1	expression	led	to	
downregulation	of	Chk1	and	reduction	of	Chk1	kinase	activity.	The	inhibition	of	Mcph1	and	Chk1	affected	the	
expression	of	a	specific	subset	of	cell	cycle–controlling	genes	and	turned	off	neural	stem	cell	proliferation	in	
neurospheres.	Furthermore,	in	vitro	silencing	of	either	Mcph1	or	Chk1	in	neurospheres	mimicked	VA-induced	
inhibition	of	cell	proliferation.	These	results	demonstrate	that	VIP	blockade	induces	microcephaly	through	
Mcph1	signaling	and	suggest	that	VIP/Mcph1/Chk1	signaling	is	key	for	normal	cortical	development.
Introduction
Autosomal recessive primary microcephaly (MCPH) is a genetic 
affection often characterized by a severe reduction of brain size with-
out cortical cytoarchitecture defect, as defined at birth by an occipi-
tal frontal circumference (OFC) below –2 SD or more from nor-
mal range (1). MCPH patients usually exhibit mild developmental 
delay associated with hyperkinesia and, most often, mild to severe 
cognitive impairment (2, 3). Seven genes are currently identified 
in MCPH-related patients, namely BRIT1/MCPH1 (BRCT–repeat 
inhibitor of hTert expression, which encodes MICROCEPHA-
LIN; locus MCPH1) (4), WDR62 (WD repeat domain 62; MCPH2) 
(5–7), CDK5RAP2 (cyclin-dependent kinase 5 regulatory associated 
protein 2; MCPH3) (8), CEP152 (centrosomal protein 152 kDa; 
MCPH4) (9), ASPM (abnormal spindle-like microcephaly-associ-
ated protein; MCPH5) (10), CENPJ (centromeric protein J; MCPH6) 
(8), and STIL/SIL (SCL/TAL1 interrupting locus; MCPH7) (11). 
While mutation-induced loss of function triggers a reduction of 
cortical expansion in MCPH-related patients, native proteins were 
found involved in cell cycle/checkpoint control (MCPH1 and STIL, 
refs. 12–15), and/or mitotic spindle dynamics (MCPH1, WDR62, 
CDK5RAP2, CEP152, ASPM, CENPJ, and STIL; refs. 8 and 16–18). In 
addition, MCPH1, CEP152, and STIL were also implicated in radia-
tion-induced DNA repair, apoptosis, and cancer (12, 19–25). Down-
stream, Checkpoint kinase 1 (CHK1), a target for MCPH1, is known 
to control progression of the cell cycle at crucial phases including 
S phase and G2/M transition (14, 15, 21, 22, 25).
Although animal models would be of great help in better under-
standing MCPH-linked mechanisms, very few of them displaying 
MCPH phenotype are available so far. Genetic invalidations of 
intrinsic factors (i.e., Stil, Chk1, breast cancer 1 [Brca1]) have been 
carried out in mice but resulted in lethal phenotypes in utero (19, 
26, 27). Two Mcph1 knockout mice were very recently described 
(28, 29). In the Mcph1/Brit1 conditional invalidation driven by 
the β-actin promoter, mutant mice exhibit mitotic and meiotic 
recombination, DNA repair defects resulting in genomic instabil-
ity, and infertility (28). However, the brain phenotype has not yet 
been reported. In the other model, which was generated by gene 
trapping leading to the deletion of the C-terminal BRCT domain 
of Mcph1, adult mice do not have detectable brain weight loss 
although no detailed neuropathology has been reported (29). In 
addition, about 1,200 genes were either upregulated or down-
regulated when compared with WT brain (29). Interestingly, 
the Nde1–/– mouse (NUDE in humans, encoding a microtubule 
organizing center–associated [MTOC-associated] protein) is the 
only published genetic mouse model with a developmental brain 
phenotype showing a significant reduction (around 20%) of the 
overall brain volume with a specific reduction of upper layers 
(30). However, loss of function of NUDE has not been reported in 
MCPH-related patients.
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Developmental processes that are controlled by the MCPH loci 
may also depend on environmental factors. Deleterious extrinsic 
factors including alcohol, caffeine, morphine, and chemothera-
peutic agents have been shown to modulate cell cycle duration 
and symmetrical versus asymmetrical divisions, resulting in limi-
tations of the number of newborn cortical neurons (31–35). How-
ever, specific molecular targets of these extrinsic factors are not 
yet elucidated, except for ionizing radiation shown to have a nega-
tive impact on brain development by interfering with the ATR/
CHK1/PCNT pathway (36). Conversely, beneficial extrinsic fac-
tors either produced by the embryo (including IGF-I and FGF10) 
or that cross the placenta barrier when produced by the mother 
(i.e., vitamin D3, thyroid hormone T3, NT3, or serotonin) can 
sustain boost or modulate embryonic brain development (37–40). 
Among these maternal factors, the vasoactive intestinal peptide 
(VIP) is produced in great amount during pregnancy (41) by lym-
phocytes present in decidual membranes (42) and elicits various 
neurotrophic actions including a major growth factor effect on 
embryogenesis, as shown previously on whole embryos treated ex 
utero with VIP (43). To date, none of these extracellular factors 
have been clearly connected with this ubiquitous machinery that 
dictates the appropriate number of neurons necessary to ensure 
the normal brain functions.
In line with these data, in the early 1990s, Gressens and cowork-
ers described a pharmacologically induced murine model of micro-
cephaly (44). In the latter, maternal VIP was challenged by a well-
characterized VIP antagonist (VA) (45–47), which, when injected 
into pregnant females during neurogenesis (E9–E11), led to corti-
cal alterations of newborn pups. These alterations involve the size 
but not the architecture of the cortex, a phenotype reminiscent of 
MCPH features in humans. Follow-up studies by the same investi-
gators have suggested that VIP action on embryonic cortical expan-
sion was related to a reduction of cell cycle duration including a 
shortening of the S phase (48). Nevertheless, at that time, no molec-
ular mechanism was offered to explain such a drastic phenotype.
In the present study, we used this animal model and sought 
after the possible mechanism by which extrinsic factors such as 
VIP control cell cycle duration. To address this issue, we aimed to 
correlate VA-induced alteration of the VIP signaling pathway with 
modulation of expression of MCPH genes and their functions 
both in vivo and in vitro using embryos, newborn mice, and neu-
rosphere-derived progenitors. We demonstrate that VIP blockade 
specifically downregulates Mcph1-Chk1 expression and function, 
ultimately leading to cortical abnormalities that closely mimic 
features described in MCPH patients.
Results
VIP blockade during neurogenesis induces microcephaly with thinner 
cortex. VIP blockade results in microcephaly in mice: however, 
the phenotype has not been described yet at the histological and 
morphometric levels. A global morphometric analysis of brains 
from P5 pups born from either VA- or PBS-injected dams was per-
formed. VA brains showed a reduced weight as compared with con-
trols at P5 and P10, without statistically significant body weight 
reduction (Supplemental Figure 1, A and B; supplemental mate-
rial available online with this article; doi:10.1172/JCI43824DS1). 
On Nissl-stained sections, a clear qualitative shrinkage of cortical 
thickness was observed (Supplemental Figure 1, C and D).
On selected coronal rostral and caudal levels of the primary 
somatosensory cortex (S1) (see Supplemental Methods), cortical 
surface (Supplemental Figure 1E) and thickness (Supplemental 
Figure 1F) were decreased in VA-treated animals as compared 
with controls. The cortical layers were thinner in VA than in con-
trols, but differences were slightly bigger in rostral than in caudal 
somatosensory areas (i.e., 19%: 789 ± 92 μm vs. 645 ± 68 μm and 
17%: 974 ± 63 μm vs. 775 ± 55 μm, respectively, n = per condition) 
(Supplemental Figure 1G).
The cortical neuronal density, assessed at the rostral level in the 
primary somatosensory cortex, did not reveal any significant dif-
ference in the number of neuronal nuclei–labeled (NeuN-labeled) 
neurons per surface unit between VA and controls (8180 ± 1085 
cells/μm2, n = 3; control, 8780 ± 778 cells/μm2, n = 4) (Supple-
mental Figure 1H). However, measurement of the thickness 
of the superficial cortical layers (II–III–IV) versus deeper layers 
(V–VI) revealed a reduction of both the superficial and deep layers’ 
thickness (Supplemental Figure 1, G and H). The use of specific 
Figure 1
VIP blockade during neurogenesis induces 
microcephaly with thinner cortex and reduction 
of both upper and lower cortical layers. (A–C) 
Coronal P6 brain sections immunostained with 
specific markers of cortical layers (A: Cux1; 
B: Satb2; C: Tbr1) show that all layers are 
reduced in thickness in VA-treated animals 
when compared with age-matched controls 
(CTRL). Scale bars: 100 μm.
Table 1
VA lengthens cell cycle in dorsal telencephalic VZ progenitors  
of E11.5 embryos
Dorsal E11.5 Ts (h)A Tc (h)B Ts/Tc
Control 5.4 ± 0.38 12 ± 0.76 0.45 ± 0.02
VA 8.5 ± 0.87 29 ± 4 0.30 ± 0.02
P value (unpaired t test) 0.0317 0.0159 0.0159
Cell cycle parameters (mean ± SEM) calculated from IdU/BrdU double 
labeling (cf. Figure 2, C and D) according to ref. 49. ALength of S phase, 
Ts = Ti/(Lcells/Scells). BTotal cell time, Tc = Ts/(Scells/Pcells). Ti, 1.5 
hours; Lcells, IdU+BrdU–; Scells, IdU+BrdU+; Pcells, total number of pro-
liferating cells, estimated by DAPI count in the VZ in the sampling area.
Downloaded from http://www.jci.org on September 8, 2017.   https://doi.org/10.1172/JCI43824
research article
3074	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 8   August 2011
markers of cortical layers (Cut homeobox 1 [Cux1], expressed in 
layers II–IV, special AT-rich sequence-binding protein 2 [Satb2]; 
expressed by a subset of neurons throughout the cortical lay-
ers with a most prominent expression in layers II–IV; and T box 
brain 1 [Tbr1], expressed in layer VI) confirmed that all layers 
were affected by VA treatment (Figure 1). Astrocyte distribution 
appeared unchanged between groups as revealed by GFAP immu-
nodetection (data not shown).
Figure 2
VA reduces cortical thickness in embryos by lengthening cell cycle during neurogenesis without inducing excess apoptosis. (A) Coronal sec-
tion of control and VA brains from E12.5 embryos stained by cresyl violet. Scale bar: 200 μm. (B) Lateral and dorsal cortical thickness of E12.5 
embryo telencephalon in control and VA groups (n = 6, unpaired t test, *P < 0.05). (C) Double-labeling BrdU (red), IdU (green), and DAPI (blue) 
at E11.5 in the dorsal telencephalic VZ in control and VA sections. Scale bars: 20 μm. (D) Schematic representation of experimental BrdU-IdU 
procedure: injection at T0 hour with IdU and at T1.5 hour (Ti) with BrdU followed by sacrifice at T2.0 hour allows identification of the 3 cell types 
shown in C: those within the S phase at T0–T1.5 but within G2/M at T1.5–T2.0 (labeled in green due to IdU-incorporation only = leaving fraction 
= Lcells = IdU+/BrdU–); cells entering S phase at T1.5–2.0 (labeled in red because of BrdU incorporation = BrdU+/IdU–); and finally cells within 
S phase at both T0 and T1.5 (labeled in yellow due to IdU/BrdU incorporation = S fraction = Scells = IdU+/BrdU+). DAPI counterstained nuclei 
in blue (Pcells). (E and F) Immunostaining for cleaved caspase-3 does not show any difference between control and VA-treated animals (n = 8 
per group, t test, *P < 0.05). Scale bars: 20 μm.
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Taken together, these data suggest that VIP blockade during early 
neurogenesis has a dramatic impact on cortical development.
VIP blockade decreases proliferation in neuroepithelial progenitors 
by increasing cell cycle length. To address whether VA could have a 
direct impact on neurogenesis, we analyzed proliferation and cell 
cycle length in embryos. Since the thickness reduction was already 
detectable as early as E12.5 in lateral telencephalic walls of VA-
treated embryos (Figure 2, A and B), we analyzed progenitor pro-
liferation 1 day before, i.e., in E11.5 VA-treated embryos and con-
trols. To assess a potential decrease in cell proliferation, we first 
measured the cell cycle length in VA-treated and control telence-
phalic samples, using an elegant method previously described (49). 
Iododeoxyuridine (IdU) was injected into E11.5 pregnant females 
followed by BrdU (50 mg/g body weight each for both) 1.5 hours 
later. Dams were sacrificed 2 hours after the first injection (Figure 
2D). As shown in Figure 2C and Supplemental Table 1, both BrdU 
and IdU labeling were reduced in VA animals. Cell cycle length cal-
culation shown on Table 1 was performed by extracting the param-
eters S phase (Ts) and total cycle (Tc) durations as well as the Ts/Tc 
ratio from the number of positive cells for BrdU, IdU, or both. In 
line with previous studies (50, 51) performed in E11.5 ventricular 
zone (VZ) control brains, Ts was approximately 5.4 hours and Tc 
12 hours. In VA-treated brains, both Ts and Tc were significantly 
lengthened: Ts approximately 8.5 hours and Tc approximately 29 
hours, confirming that VA-induced VIP blockade between E9 and 
E11 reduces VZ progenitor proliferation by increasing the dura-
tion of both the S phase and the whole cell cycle.
At this stage, the number of apoptotic cells (cleaved caspase-3 
and TUNEL positive) in the dorsal VZ was similar in VA and con-
trol telencephalon (Figure 2, E and F and data not shown).
VIP blockade accelerates cell cycle exit and leads to early differentia-
tion of cortical progenitors. Since the reduction of VZ progenitors 
appeared secondary to the cell cycle lengthening in VA-treated 
telencephalon, we aimed to characterize the cell fate of these pro-
Figure 3
VA-induced microcephaly trig-
gers cell cycle exit and early dif-
ferentiation of cortical progenitors 
in embryos. (A and B) Immuno-
fluorescent staining for p27kip1 
on coronal E11.5 sections in dor-
sal telencephalon of VA-treated 
embryos compared with controls. 
Scale bars: 20 μm. The labeling 
index (number of p27kip1-positive 
cells over the total number of nuclei 
stained by DAPI) is increased in 
VA-treated embryos as compared 
with controls (n = 7 per group, 
unpaired t test, **P < 0.01). (C) 
Immunofluorescent staining for 
Dcx on coronal E12.5 sections in 
dorsal telencephalon of VA-treated 
embryos compared with controls. 
Postmitotic Dcx-positive neu-
rons are observed in VA-treated 
embryos in LGE and in the dorsal, 
medial, and lateral preplate, while 
positive staining remained almost 
absent in controls at E12.5. Scale 
bars: 200 μm). Lower panel shows 
high-magnification photographs of 
Dcx-immunoreactive cells in boxes 
1 and 2. Scale bars: 50 μm. (D) 
Calretinin immunoreactivity at the 
same level as mentioned above. 
Note the intense labeling in LGE 
(box 2) and in the dorsal (box 1), 
medial, and lateral preplates, which 
are undetectable in controls. Scale 
bars: 200 μm. Lower panel shows 
high-magnification photographs of 
calretinin-immunoreactive cells in 
boxes 1 and 2.
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genitors. Therefore, we studied at E11.5 the expression pattern 
of p27kip1, a factor known to promote cell cycle exit of cortical 
progenitors (52). p27kip1-positive cells were highly increased in 
the dorsal telencephalon of VA-treated embryos as compared with 
age-matched controls, indicating that VIP blockade during early 
neurogenesis significantly promotes VZ progenitors to exit the 
cell cycle (Figure 3, A and B).
To investigate whether this loss of progenitors could influence 
the normal cell differentiation during early neurogenesis and 
corticogenesis phases, we assessed the doublecortin (Dcx) immu-
Figure 4
VA acts by interfering with VIP/VPAC signaling pathway and PKA activation. (A) VIP receptors and VPAC1 and VPAC2 expression levels as 
assessed by quantitative RT-PCR performed from neurosphere-derived progenitors and E12/E16 telencephalon. VPAC1 and VPAC2 receptors 
are mainly expressed in early stages, while PAC1 expression increased throughout the development. (B–H) BrdU incorporation assay performed 
on E10.5 neurosphere-derived progenitors. VIP stimulates proliferation of E10.5 neurosphere-derived progenitors in a dose-dependent manner 
(B). This effect is completely abrogated by VA at concentrations as low as 0.1 nM (C). VA alone decreases proliferation of neurosphere-derived 
progenitors compared with PBS (D). VPAC1 (E and F) and VPAC2 (G) agonists mimic VIP-induced BrdU incorporation. VIP stimulatory effect 
on BrdU incorporation is mimicked by the adenylate-cyclase activator FSK but is inhibited by H89 or KT5920, 2 separate inhibitors of PKA (H). 
(n = 8 per group, unpaired t test, *P < 0.05, **P < 0.01, or ***P < 0.001 between treatments and controls; or #P < 0.05, ##P < 0.01, or ###P < 0.001 
between VIP and other treatments).
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noreactivity in the telencephalon of E12 control and VA-treated 
embryos. Dcx is a microtubule-associated protein whose expres-
sion underlines mitosis exit and that is commonly used as an early 
marker of newborn postmitotic neurons (53). Dcx was expressed in 
VA-treated cortices with highest signals in lateral ganglionic emi-
nence (LGE), while it remained undetectable in control cortices 
at this stage (Figure 3C). Similarly, immunostaining at E11.5 for 
Calretinin, a marker for Cajal-Retzius neurons, was not visible in 
controls while it strongly labeled VA-treated cortices (Figure 3D). 
Interestingly, Dcx- and Calretinin-positive postmitotic neurons 
were predominantly detected in the dorsal, lateral, and medial 
preplate and in LGE from VA-treated cortices (Figure 3, C and D).
Figure 5
VA treatment affects specifically the expression of Mcph1 genes in vivo. (A–E) Expression levels of all known Mcph genes: Mcph1 (A), Wdr62 
(B), Cdk5rap2 (C), Cep152 (D), Aspm (E), Cenpj (F), and Stil (G) assessed by quantitative RT-PCR on RNA samples extracted from telen-
cephalon of embryos (control or VA-treated) from E12 to P0. Parallel to the time-dependent reduction in Mcph gene expression, VA induced 
a significant decrease in Mcph1 expression (n = 8, run in duplicate, 1-way ANOVA followed by Bonferroni’s post-test, *P < 0.05, **P < 0.01, or 
***P < 0.001) compared with controls (A). In contrast, no clear difference was observed between control and VA samples at the corresponding 
ages for Wdr62, Cdk5rap2, Cep152, Aspm, Cenpj, and Stil (B–G). (H and I) Rescue experiments performed on E16 telencephalic samples 
by quantitative RT-PCR. Mcph1 transcription (H) is also upregulated by VIP (*P < 0.05, **P < 0.01, or ***P < 0.001), while coinjection of VA 
significantly represses VIP-induced overexpression (#P < 0.05, ##P < 0.01, or ###P < 0.001). Aspm expression used herein as negative control 
remains unaffected by VIP, VA, or both (I).
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Together, our results indicate that VIP blockade during early 
neurogenesis promotes cell cycle exit and premature neuronal dif-
ferentiation of VZ progenitors in both dorsal and ventral telen-
cephalon without increased apoptosis.
VIP blockade inhibits the neurotrophic VIP signaling through cAMP-
coupled VPAC receptors. To further dissect VIP signaling in our 
model, we first asked whether VIP receptors are expressed during 
neurogenesis. To this end, we measured the level of expression of 
the 3 known VIP and PACAP receptors (Vpac1, Vpac2, and Pac1) by 
quantitative PCR using RNA extracts from E12 and E16 embry-
onic forebrains and neurosphere-derived progenitors isolated 
from E10.5 forebrains. VIP and PACAP may actually interact with 
all 3 receptors, although VPAC2 and PAC1 are the predominant 
forms at these early stages of brain development. As shown in Fig-
ure 4A, Vpac1, Vpac2, and Pac1 were expressed in neural stem cells 
as well as E12 and E16 telencephalon.
To dissect the VIP signaling path-
way during the intense prolifera-
tive period of neural progenitors, 
we studied proliferation of neu-
rosphere-derived progenitors with 
a BrdU incorporation assay (see 
Methods) in the presence of VIP, 
VIP agonists, VA, and activators or 
inhibitors of the cAMP/PKA path-
way. As shown in Figure 4, B and C, 
VIP stimulated the proliferation of 
progenitors in a dose-dependent 
manner and with a classical bell-
shaped curve (54), and its maximal 
effect on BrdU incorporation was 
completely abolished in the pres-
ence of VA. VA alone reduced BrdU 
incorporation (Figure 4D). The 
proliferative effect of VIP at nano-
molar concentration that excluded 
an effect through PAC1 receptor by 
definition (55) could be mimicked 
by both VPAC1 (Figure 4, E and F) 
and VPAC2 agonists (Figure 4G). 
Finally, the VIP stimulatory effect 
was completely abolished by 2 dif-
ferent PKA inhibitors (H89 and 
KT5920) and mimicked by for-
skolin (FSK), an adenylate cyclase 
activator (Figure 4H). Together, 
these data suggest that VIP-
induced proliferative actions are 
mediated by VPAC receptors posi-
tively coupled with a cAMP/PKA 
signaling pathway and that this 
pathway is blocked by VA.
VIP blockade leads to in vivo inhibi-
tion of Mcph1 expression. To explore 
a putative crosstalk between VIP 
signaling and MCPH-related genes, 
we analyzed Mcph gene expres-
sion in the telencephalon of both 
VA-treated animals and controls 
at different stages. RNA samples 
were extracted from the telencephalon of control and VA-treated 
embryos between E12 and P0. Quantitative RT-PCR experi-
ments were performed to measure the expression levels of differ-
ent genes known to be relevant in human microcephaly, namely 
MCPH1, WDR62, CDK5RAP2, CEP152, ASPM (commonest cause 
of MCPH), CENPJ, and STIL. All of these genes showed a similar 
ontogenic pattern with a very high expression during neurogenesis 
and then decreased until birth. However, only Mcph1 was signifi-
cantly downregulated in the telencephalon of VA-treated embryos 
during the normal peak of expression (between E12 and P0 as 
compared with controls) (Figure 5, A–G). Moreover, this specific 
effect of VA on Mcph1 expression was also observed at the pro-
tein level as shown by Western blot (Supplemental Figure 2). To 
further assess the specificity of VA on Mcph1 and its downstream 
targets, we carried out similar experiments on E16 embryos after 
treatment with VIP, VA, or both between E9 and E11 (Figure 5, 
Figure 6
VA treatment affects Mcph1 gene expression in E10.5 neurosphere-derived progenitors through VPAC1-
PKA signaling. (A and B) Mcph1 and Aspm (used as control) expression levels assessed by quantitative 
RT-PCR isolated from neurosphere cultures treated with VIP analogues. Note that only VPAC1 agonist 
was able to perfectly mimic VIP effects (n = 4 per group, run in duplicate, 1-way ANOVA, *P < 0.05, 
**P < 0.01, or ***P < 0.001). Once again, VPAC1 agonist failed to induce any change in Aspm expres-
sion. (C and D) Similar to the above experiment, neurosphere cultures were treated with VIP, VA, VIP 
plus VA, VIP plus H89 and KT5720, 2 PKA inhibitors, to analyze Mcph1 or Aspm gene expression. 
VIP-induced stimulation of transcript levels (mean ± SEM) compared with controls (n = 4 per group, 
run in duplicate, 1-way ANOVA, *P < 0.05, **P < 0.01, or ***P < 0.001); VA reduces Mcph1 transcript 
expression. VIP effects on Mcph1 expression are abolished in the presence of VA (##P < 0.01, or 
###P < 0.001). 3 inhibitors of PKA reduce Mcph1 expression, mimicking VA effects. Aspm gene expres-
sion was not modified by these treatments.
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H and I). While VA reduced the basal level of expression of Mcph1, 
as expected, VIP had the opposite effect. Interestingly, VIP was able 
to rescue the VA-induced inhibition of Mcph1 (Figure 5H), while 
Aspm, used as a negative control, remained unchanged (Figure 5I). 
In situ hybridization performed at E12.5 showed that, in control 
embryos, Mcph1 was expressed along the whole telencephalon in 
almost all cells of the neuroepithelium (Supplemental Figure 3). In 
contrast, in VA-treated embryos, Mcph1 expression was restricted 
to the outer part of the neuroepithelium of the rostral telencepha-
lon (Supplemental Figure 3). Taken 
together, these data demonstrate that 
VIP blockade during neurogenesis 
specifically reduces the expression of 
Mcph1 in embryo telencephalon.
VA acts through VPAC1 receptors to block 
Mcph1 expression in neurosphere-derived 
progenitors. To further decipher the sig-
naling pathway triggered by the VIP in 
our model, we used an in vitro approach 
based on neurosphere-derived progeni-
tors. As observed in vivo, VA reduced 
Mcph1 expression, VIP stimulated Mcph1 
expression, and this latter effect was 
blocked by cotreatment with VA (Fig-
ure 6). VPAC1 agonist but not VPAC2 
agonist mimicked VIP-induced expres-
sion of Mcph1 (Figure 6A) and had no 
effect on Aspm expression (Figure 6B). 
This suggests that, in the same way as in 
the in vivo experiments, VA specifically 
inhibits Mcph1 through VPAC1 signal-
ing in neurosphere-derived progenitors. 
In vitro, addition of H89 or KT5720 
also resulted in significant reduction 
in expression levels of Mcph1, confirm-
ing the involvement of PKA activity in 
the regulation process (Figure 6C). Again, no effect was observed on 
Aspm expression (Figure 6D).
The effect of VIP on proliferation of neurosphere-derived progenitors is abol-
ished in the absence of Mcph1. To confirm the specificity of VIP effects 
on Mcph1 signaling, we next aimed to silence Mcph1 in neurosphere-
derived progenitors. Cells were transduced with lentiviral vectors 
expressing shRNAs, which, once converted into siRNAs, specifically 
targeted Mcph1 mRNA. The expression level of Mcph1 was analyzed 
by quantitative PCR and Western blot. Data revealed a signifi-
Figure 7
Mcph1 silencing reproduced VA effects 
on VIP-induced proliferation of neural 
progenitors. (A–B) Mcph1 and Aspm 
gene expression as assessed by quanti-
tative RT-PCR from neurosphere-derived 
progenitors transduced by Mcph1-spe-
cific lentiviral-mediated shRNA, Mcph1-
specific shRNA2, and Mcph1-specific 
shRNA3 specifically inhibits Mcph1 tran-
script expression (n = 3 per group, 1-way 
ANOVA, *P < 0.05, **P < 0.01). The nega-
tive controls (empty virus and nontarget 
shRNA) failed to modulate Mcph1 expres-
sion. Knockdown of Mcph1 by shRNA2 
and shRNA3 results in lost of Mcph1 
protein at DIV5 after transduction (A, right 
panel). Knockdown of Mcph1 fails to affect 
Aspm expression (B). (C) BrdU incorpora-
tion by neurosphere-derived progenitors 
treated by Mcph1-specific shRNA in the 
presence of VIP or PBS (control). Note 
that Mcph1 shRNA2 and shRNA3 abolish 
VIP-induced proliferation.
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Figure 8
VA treatment reduces Chk1 and 
Brca1 gene expression both in vivo 
and in vitro. (A–D) Chk1 and Brca1 
expression levels assessed by 
quantitative RT-PCR on RNA sam-
ples extracted from telencephalon of 
embryos (control or VA-treated) from 
E12 to P0. VA induced a significant 
decrease in Chk1 (A) and Brca1 (B) 
expression (n = 8 per group, 1-way 
ANOVA followed by Bonferroni’s 
post-test, *P < 0.05, **P < 0.01, 
or ***P < 0.001). In rescue experi-
ments performed at E16 by quan-
titative RT-PCR, VIP upregulates 
both Chk1 and Brca1, while coin-
jection of VA and VIP significantly 
represses VIP-induced overexpres-
sion of both genes (at #P < 0.05, 
##P < 0.01, or ###P < 0.001) (C and 
D). (E–H) Chk1 and Brca1 expres-
sion levels in neurosphere-derived 
progenitors. Chk1 is upregulated 
by VIP and blocked by VA (E and 
G). VPAC1 agonist increases Chk1 
transcript level, whereas VPAC2 
agonist has no effect (E). VIP mildly 
increases Brca1 gene expression 
(F and H), while VA significantly 
reduces Brca1 gene expression. 
H89 inhibits both Chk1 and Brca1 
gene expression (G and H), mimick-
ing VA effects.
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cant inhibition of Mcph1 expression by 2 separate Mcph1-targeting 
shRNAs (Figure 7A). This selective downregulation of Mcph1 failed 
to trigger any effect on Aspm, used as a negative control (Figure 7B). 
Importantly, stimulation of cell growth by VIP was abolished by the 
selective Mcph1-targeting shRNAs (Figure 7C) suggesting that Mcph1 
is required to mediate the effects of VIP on neurogenesis.
VA inhibits Mcph1-Chk1 signaling both in vivo and in vitro. It has been 
shown that MCPH1 regulates CHK1 and BRCA1 expression (14, 
15). CHK1 and BRCA1 are involved in DNA repair and cell cycle 
check point control (56–59) and also play a role in proliferation of 
undamaged cells (22, 25, 56, 60–62). However, their roles in neuro-
genesis have not been investigated.
Before addressing the impact of VIP and VA on the expression 
of Chk1 and Brca1, we confirmed that in neurosphere-derived pro-
genitors, Mcph1 regulates Chk1 and Brca1 expression, using Mcph1-
targeting shRNAs (Supplemental Figure 4).
To determine whether Mcph1 targets are regulated by VIP, we stud-
ied Chk1 and Brca1 expression in the telencephalon of VA-treated 
embryos and in neurosphere-derived progenitors by quantitative 
PCR and Western blot. Expression of Chk1 and Brca1 genes was found 
to be decreased by in vivo VA treatment (Figure 8, A and B). Western 
blot analysis of VA-treated embryos confirmed the significant reduc-
tion of Chk1 and showed a similar trend for Brca1 (Supplemental 
Figure 5). VIP increased in vivo Chk1 and Brca1 expression and was 
able to rescue VA-induced inhibition of Chk1 and Brca1 (Figure 8, 
C and D). In line with the in vivo data, VIP significantly increased 
Chk1 expression in neurosphere-derived progenitors (Figure 8E). 
Its effects on Chk1 expression were mimicked by a VPAC1 agonist 
but not by a VPAC2 agonist (Figure 8E). VA inhibited Chk1 expres-
sion, and this effect was mimicked by H89 (Figure 8G). Although 
it did not reach significance, there was a trend toward an increased 
expression of Brca1 following VIP treatment of neurosphere-derived 
progenitors (Figure 8H). VA significantly inhibited Brca1 expression, 
and this effect was mimicked by H89 (Figure 8H). Together, these 
data indicate that VA inhibits Mcph1-Chk1-Brca1 signaling both in 
vivo and in vitro through the VPAC1/PKA signaling pathway.
Figure 9
The effects of VIP on neurosphere proliferation are abolished in the absence of Chk1. (A and B) Chk1 expression levels assessed by quantita-
tive RT-PCR on extracts from neurosphere-derived progenitors transduced by lentiviral-mediated–specific Chk1-specific shRNA. Knockdown 
of Chk1 gene expression by sequences shRNA1, shRNA2, and shRNA3 significantly reduces both mRNA levels (A) and protein contents (B), 
while sequence shRNA4 failed to induce any significant silencing. (C) BrdU incorporation in neurosphere-derived progenitors transduced by dif-
ferent control lentiviral vectors and the specific Chk1 shRNA1 and shRNA 2. Silencing the Chk1 gene obliterates VIP-induced mitogenic action 
in neurosphere-derived progenitors. (A) n = 3 per group, 1-way ANOVA, *P < 0.05; **P < 0.01. (B) n = 3 per group, unpaired t test. (C) n = 8 per 
group, unpaired t test.
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Chk1 is required for VIP proliferative effects on neurosphere-derived 
progenitors. To assess whether Chk1 is also necessary to mediate 
the effect of VIP, we knocked down the expression of Chk1 in neu-
rospheres. Neurospheres were transduced with lentiviral vectors 
expressing various shRNAs, which, once converted into siRNAs, 
specifically targeted Chk1 mRNA. Chk1 downregulation was 
checked by quantitative PCR and Western blot (Figure 9, A and B) 
and showed that, out of 4 different vectors, only the shRNA4 len-
tiviral vector failed to inhibit Chk1 expression. BrdU incorpora-
tion experiments were carried out to evaluate VIP effects on neu-
rosphere proliferation (Figure 9C) in the lentiviral-transduced 
cells. As shown in Figure 9C, VIP failed to stimulate proliferation 
in Chk1-shRNA1– and Chk1-shRNA2–transduced cells but was 
still able to induce that of cells containing the control sequence or 
Chk1-shRNA4 (used here as a negative control). These data indi-
cate that Chk1 is required for VIP mitotic effects on neurosphere-
derived progenitor proliferation.
VIP blockade interferes with cell cycle by modulating Chk1 functions. To 
determine whether VA affects Chk1 function in addition to Chk1 
expression, we assessed Chk1 kinase activity in vivo (in forebrain/
telencephalon from control and VIP- and VA-treated embryos 
between E12 and P0) and in vitro (in neurosphere-derived pro-
genitors treated by PBS, VIP, or VIP plus VA). At each stage in vivo 
(Figure 10A) and in neurosphere-derived progenitors (Figure 10B), 
Chk1 kinase activity was strongly reduced in the presence of VA 
and strongly enhanced upon VIP stimulation. As expected, H89 
blocked VIP effect, thus mimicking VA action, while FSK mir-
rored VIP activity in vitro (Figure 10B). These data indicate that 
VIP blockade affects Chk1 function, most likely by modulating 
the cAMP/PKA pathway.
To determine whether key checkpoints of cell cycle known to be 
targets of Chk1 were also affected in our model, we analyzed the 
expression of cell division cycle 25C (Cdc25), Cyclin B, and cyclin-
dependent kinase 1 (Cdk1) (involved in regulation of G2/M transi-
tion) and Cyclin A and Cdk2 (regulation of S phase) by quantita-
tive PCR. As shown in Figure 10, C–E, VA treatment resulted in a 
strong decrease of Cdc25, cyclin B, and Cdk1 expression in vivo. The 
in vitro approach accordingly showed that VA completely abolishes 
the effects of VIP on the expression of these genes (Figure 10, F–H). 
In contrast, expression of Cdk2 and Cyclin A remained unchanged 
both in vivo and in vitro (data not shown). These data indicate 
that VIP blockade affects specific cell cycle checkpoints and sug-
gest that VIP blockade has an impact on the G2/M transition.
To determine whether this effect was mediated by Chk1, we 
analyzed the expression of these G2/M transition checkpoints 
following downregulation of Chk1 expression through the lenti-
viral-mediated RNA interference approach using the shRNAs spe-
cifically directed against Chk1. Downregulation of Chk1 resulted 
in a reduced expression of Cdc25, Cyclin B, and Cdk1 expression, 
indicating that the effect observed upon VA treatment was medi-
ated by Chk1 (Figure 10, I–K).
Taken together, these data indicate that VIP blockade interferes 
with the cell cycle by affecting Chk1 activity and the subsequent 
modulation of targets involved in G2/M transition.
Discussion
The basis of the high degree of encephalization in humans is not 
understood. Discovery of the microcephaly locus was an impor-
tant step in this process, as it offered an insight into a set of loci 
that controlled cortical size without an adverse effect on corti-
cal patterning. Interestingly, evolutionary studies do not seem 
to support the hypothesis that these loci then must have been 
positively selected for during vertebrate evolution. In this context, 
there are several external factors that also lead to a large varia-
tion in cortical size. Therefore one possible reason for a lack of 
evidence for the strong positive selection in the MCPH loci is that 
the high degree of encephalization during evolution is the result 
of a combination of environmental factors that modulate these 
genetic loci and therefore the genetic loci itself is but only half the 
story. To date there has been no evidence linking environmental 
factors to genes that have been shown to play a role in regulating 
cortical size, and this is a subject of speculation. In this study, we 
show for what we believe is the first time that a maternal factor, 
VIP, modulates MCPH genetic loci that have been associated with 
cortical expansion and thus points to a mechanism by which a 
combination of genetic selection and maternal factors may play a 
role in regulating cortical size.
The most salient feature of the present study is the demonstra-
tion that, in mice, VIP blockade–induced microcephaly involves 
Mcph1 downregulation, linking a maternal factor to the molecular 
machinery, which controls the proliferation of neural cell precur-
sors. In addition, in this model, interfering with the expression 
and/or function of Chk1, a known target of Mcph1, appears as a key 
mechanism for the VA-induced blockade of the cell cycle. Finally, 
VIP blockade slows down proliferation of VZ progenitors through 
lengthening of cell cycle duration and acceleration of cell cycle exit 
and progenitor differentiation.
Is the VA-induced microcephaly a relevant model for human MCPH? 
Several lines of evidence support that the present model mimics 
different key aspects of human MCPH. Indeed, blockade of VIP 
signaling during neurogenesis induces a reduction in brain weight, 
in cortical thickness, and in cortical surface, these anomalies 
being reminiscent of the cortical phenotype observed in patients 
with MCPH. In addition, VIP blockade induces the inhibition of 
expression of the Mcph1 gene, 1 of the 7 known genes implicated in 
Figure 10
Chk1 kinase activity and expression of key cell cycle regulators down-
stream of Chk1 are reduced by VA. (A) Chk1 kinase activity assessed 
by kinase essay on telencephalon or cortical extracts from E12 to P0 
embryos and newborns that received VA, VIP, or both treatments. At 
the 3 embryonic ages, Chk1 kinase activity (mean ± SEM) follows the 
same time-dependent decrease in controls. VIP treatment stimulates 
Chk1 activity (n = 5 per group, run in duplicate, 1-way ANOVA, ##P < 
0.01), while VA suppresses it (*P < 0.05, **P < 0.01, or ***P < 0.001). 
(B) Chk1 kinase activity on protein extracts isolated from neurosphere 
cultures after treatment with VIP or VIP plus VA or cAMP/PKA agents. 
VIP stimulates kinase activity in neurospheres; such an enhancement 
was counterbalanced by cotreatment VIP plus VA. H89 inhibited the 
kinase activity (**P < 0.01), while FSK enhanced it. (C–E) Transcription 
levels of specific key cell cycle regulators downstream of Chk1 (Cdc25, 
cyclin A/B Cdk1, and Cdk2 genes) assessed by quantitative RT-PCR. 
Only Cdc25, Cyclin B, and Cdk1 transcripts are significantly repressed 
(n = 8, 1-way ANOVA) by VA treatment, but no change is seen in Cdk2 
and Cyclin A levels (not shown). (F–H) Similar experiments conducted 
in neurosphere-derived progenitors. VIP upregulates Cdc25 (F) Cyclin 
B (G), and Cdk1 (H) expression; this effect was inhibited by VA treat-
ment. (I–K) Efficient Chk1 targeting by lentiviral-mediated vectors 
expressing shRNAs (1, -2, and -3) downregulated Cdc25 (I), cyclin B 
(J), and Cdk1 (K) expression (n = 3, run in duplicate, 1-way ANOVA).
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MCPH. In contrast, the expression of the other known Mcph genes 
is not affected by VA, supporting the specificity of the effects. 
Therefore, we believe that the VA model is the first that is relevant 
for MCPH1-related human microcephalies.
How does VIP regulate Mcph1 expression? Pharmacological and 
mRNA expression data support the hypothesis that VA effects 
in cell cycle and brain growth are mediated through VPAC1 
receptors expressed on NSC progenitors. In agreement with this 
hypothesis, VPAC1 mRNA is highly expressed in the VZ of E14 
rat embryos (63). As classically described for VPAC1 receptors 
(64), the transduction pathway implicated in VA effects involves 
the cAMP/PKA pathway, as demonstrated by the use of H89 and 
FSK. When activated, cAMP-dependent protein kinase A releases 
its catalytic subunits, which translocate to the nucleus and induce 
cellular gene expression by phosphorylating CREB (65). CREB 
then mediates the activation of cAMP-responsive genes by bind-
ing as a dimer to a conserved cAMP-responsive element (CRE), 
TGACGTCA (66–68). Of interest, the search for such TGACGTCA 
palindromic octamers in 50 kb of genomic DNA upstream 
of all 7 mouse Mcph genes revealed the presence of 3 distinct 
CRE sequences in Mcph1 (located at 15.2 kb, 19.6 kb, and 37 kb 
upstream of the first exon), 1 CRE sequence in Wdr62 (located at 
15 kb upstream of the first exon), and 1 CRE sequence in Cep152 
(4.88 kb upstream of the first exon), but failed to reveal any CRE 
sequence upstream of Cdk5rap2, Aspm, Cenpj, and Stil. These find-
ings support the idea that the specific Mcph1 regulation by VIP 
involves the cAMP/PKA pathway. We cannot exclude that other 
transduction pathways are involved in VIP effects since (a) VIP has 
been shown to activate other pathways including PKC and MAPK 
pathways (69), and (b) our preliminary screen of transduction 
inhibitors showed that PKC blockade, but not MAPK blockade, 
partially reversed VIP effects (data not shown).
How does Mcph1 downregulation lead to blockade of neural cell prolifera-
tion? MCPH1 has been shown to regulate the expression of CHK1 
and BRCA1 (14, 15). In the present study, inhibition of Mcph1, 
through VA or direct gene silencing, induced a downregulation 
of Chk1 and Brca1 in neural progenitors both in vivo and in vitro. 
Since the effects of VA and Mcph1 inhibition on Chk1 expression 
were of a larger amplitude than those observed on Brca1 expres-
sion, we focused our study on Chk1 inhibition and its impact on 
progenitor proliferation, although future studies will be necessary 
to determine whether Brca1 inhibition participates as well in the 
reduced proliferation observed with VA treatment.
CHK1, when activated through the phosphorylation of several 
C-terminal residues, displays a kinase activity, inducing phos-
phorylation of numerous downstream proteins including key cell 
cycle regulators (58, 59). In addition, more recent data support 
the hypothesis that CHK1 binds to chromatin and has a direct 
transcriptional activity (70–72). In terms of biological effects, a 
large body of literature implicates CHK1 in DNA repair (58, 73). 
However, more recently, CHK1 has also been shown to regulate 
the cell cycle of cells with undamaged DNA through a mechanism 
most likely independent (phosphorylation at a different residue) 
of DNA repair (22, 25, 60, 61, 74). Indeed, depletion of CHK1 
in somatic cells under unperturbed conditions induces S-phase 
arrest and repression of CYCLIN B1 and CDK1 expression (70). 
Interestingly, Chk1–/– mice die at E6.5, further supporting a role 
of Chk1 during normal embryonic development (75). In the pres-
ent study, we provide experimental data supporting the hypoth-
esis that downregulation of Chk1 is sufficient to slow down the 
proliferation of neural progenitors. The underlying mechanism 
could involve phosphorylation of proteins controlling the mitotic 
cycle through Chk1 kinase activity and/or transcription of genes 
controlling cell cycle progression such as the cyclin-dependent 
cyclin Cdc25 and cyclin B and the cyclin-dependent kinase Cdk1. Of 
interest, in agreement with previous studies showing that CHK1 
depletion induces S phase (70), the present study shows that VA 
treatment induces S-phase lengthening of VZ neural progenitors.
What are the clinical implications of the modulation of neural cell prolif-
eration by a maternal factor? In neural progenitors, the cell cycle is 
regulated in a tight, specific, and timely manner (for review, see ref. 
76) and the molecular mechanisms underlying this control seem 
to be largely conserved through evolution of mammals (77–79).
VIP has previously been shown to be a maternal factor acting on 
early brain development in rodents (80). Similarly, some data also 
suggest that maternal VIP could act on the embryonic and fetal 
brain in humans (41). Here, we demonstrate that administration 
of VA to pregnant mice during neurogenesis induces embryonic 
microcephaly with as much as 20% reduction of overall cortical 
thickness. This VA effect is mediated through the regulation of the 
expression and/or function of Mcph1 and Chk1, which are impor-
tant regulators of the cell cycle. Our data strongly suggest that 
environmental factors, including maternal ones, can influence 
the tightly controlled molecular machinery of neural progenitor 
proliferation. Comparable modulation of this intrinsic molecular 
machinery has been described for irradiation that induces murine 
microcephaly through Aspm gene inhibition (81). Together, these 
data raise the hypothesis that other environmental factors could 
impinge on the intrinsic control of neural progenitor proliferation 
and therefore modulate the final size of the brain.
Methods
Animals. All animal experiments were carried out according to protocols 
approved by the institutional review committee (Bichat-Robert Debré Ethi-
cal Committee, Paris, France) and meet stipulations of the Guide for the 
Care and Use of Laboratory Animals (NIH, Bethesda, Maryland, USA). All 
experiments were performed in Swiss mice (Elevage Janvier).
The day of vaginal plug was considered E0.5. Pregnant mice were killed 
by cervical dislocation. Embryos were harvested in cold PBS and fixed 
overnight in freshly prepared 4% PFA. For immunohistochemistry, they 
were then either dehydrated in ascending grades of ethanol and embed-
ded in paraffin or cryoprotected in 10% sucrose overnight and embedded 
in 7.5% gelatin/10% sucrose solution prior to flash freezing in isopentane. 
Tissues were later cut sagitally at 10 μm on cryostat or coronally at 7 μm 
on microtome. Newborn and adult animals were anesthetized with iso-
flurane and intracardiacally perfused with a 0.9% NaCl solution followed 
by 4% PFA. Brains were dissected and postfixed either overnight in 4% 
PFA and cryopreserved in gelatin/sucrose or in 4% formol for 4 days prior 
to embedding in paraffin. For in situ hybridization, embryos were fixed 
in 4% PFA overnight, then cryoprotected in 30% sucrose overnight and 
embedded in 7.5% gelatin/30% sucrose solution, frozen in isopentane, and 
cut coronally at 10 μm. In situ hybridization was performed according 
to Ravassard et al. (82) using a digoxigenin-labeled RNA antisense probe 
corresponding to nt 1-1146 of Mcph1.
Animal injections. Pregnant Swiss mice were injected intraperitoneally twice 
a day (8–9 am and 6–7 pm) between E9.5 and E11.5 with 50 μl of either PBS 
(vehicle) or VA (hybrid of VIP and neurotensin, which is a competitive antag-
onist of VIP receptors (83), or again VIP, according to the original protocol 
designed by Gressens et al. (43, 44). Both peptides were purchased from 
Bachem and injected at the final concentration of 2 μg/g body weight.
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Cell cycle study, BrdU, and IdU injections. On E11.5, IdU was injected 1 hour 
after the latest VA injection into pregnant females followed by BrdU injec-
tions (50 mg/g body weight each) performed 90 minutes later. Dams were 
sacrificed 2 hours after the IdU injection according to the original proto-
col schematically depicted on Figure 2C. Embryos were fixed with 4% PFA, 
cut (10 μm cryostat sections), and processed for double immunostaining 
(see below). Sections were immunolabeled with monoclonal anti-BrdU 
antibodies raised in mouse or rat that recognized either the 2 analogs or 
BrdU alone, respectively.
Histology, immunohistochemistry. Histopathological features of embryonic 
telencephalon or brains were studied by analyzing E11.5, E12.5, and P5 
control or treated Swiss mice. Tissues were processed for histology and 
immunohistochemistry as described in Supplemental Methods. BrdU and 
p27kip1 antibodies were from BD, BrdU and Dcx antibodies from Abcam, 
Calretinin and Calbindin antibodies from Swant, NeuN antibodies from 
Chemicon, GFAP antibody from Dako, cleaved caspase-3 antibody from 
Cell Signaling, Cux1 antibody from Santa Cruz Biotechnology Inc., Satb2 
and Tbr1 antibodies from Abcam. TUNEL was performed using the In Situ 
Cell Death Detection Kit, Fluorescein, from Roche.
Quantifications. Quantification of cortical thickness, surface, and NeuN 
stainings was performed on primary somatosensory cortex (S1) (see Sup-
plemental Methods). Quantification of DAPI, BrdU-IdU C–Caspase-3 and 
p27kip1 (at E11.5) and Dcx and Calretinin (at E12.5) staining were per-
formed on images from the dorsal telencephalon (see Supplemental Meth-
ods). For all quantifications, the embryos and brains (6 to 8 per group) 
were taken from at least 2 litters.
Neurosphere-derived progenitor culture. Primary neural stem cell cultures or 
neurospheres were established from the forebrain of embryos at gestation 
E10.5 using trypsin dissociation as described in Supplemental Methods.
Drug administration was performed at 3 days in vitro after the first pas-
sage of neurospheres. Neural stem cells were harvested at 4 and 20 hours 
after treatment for BrdU experiments and RNA extraction, respectively. 
Peptides including VIP, VA, VPAC1 agonist (VIP[A11A22A28]) (64), and VPAC2 
agonist (VIP[A19K27K28]) (84) were used at final concentrations ranging from 
10 pM to 1 μM, while signaling modulators such as H-89 and FSK (Calbio-
chem) were used at 20 and 30 μM, respectively.
Cell proliferation studies. BrdU incorporation assay (Cell Proliferation Kit; 
Roche) was performed on neurosphere-derived progenitors according to 
the manufacturer’s instructions as described in Supplemental Methods.
Western blot. Freshly excised cortices were soaked into cell lysis buffer 
purchased from Cell Signaling and supplemented with protease inhibitors 
including 1 mM sodium orthovanadate, 1 μg/ml leupeptin, and 10 μM 
PMSF. Total proteins, 20 or 60 μg /lane, for cell and tissue extracts, respec-
tively, were loaded onto 12% SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes (GE Healthcare). Membranes were probed with 
mouse anti-actin (1/10,000; Chemicon), anti-BRCA1 (1/200; Chemicon), 
rabbit anti-MCPH1 (1/500; Abcam), anti-CDK5RAP2 (1/2000; Bethyl), 
anti-ASPM (1/200; Novus), anti-CENPJ (1/800; Abcam), anti-STIL (1/500;, 
Abcam), and goat anti-CHK1 (1/1,000; R&D) antibodies. Antibodies were 
revealed by horseradish peroxidase–coupled conjugates, and the staining 
intensity was analyzed with the ImageJ program (NIH).
RNA extraction and relative quantification of gene expression by real-time PCR. 
Samples were isolated from animals aged from E12 to P40. Forebrains and 
cortices were dissected and total RNA was extracted as previously described 
(85). After RT was performed using iScript cDNA kit (Bio-Rad), real-time 
RT-PCR were performed as described elsewhere (86). Primer sequences are 
listed in Supplemental Table 2.
Kinase assay. Chk1 kinase assay was performed on telencephalon or cortice 
extracts or neurosphere-derived progenitors using Active Chk1 Kinase IP-Kinase 
Assay (DuoSet IC; R&D Systems) as described in Supplemental Methods.
Lentiviral transduction. A set of 3 lentiviral vectors carrying different shR-
NAs targeting Mcph1 and 4 lentiviral vectors carrying different shRNAs 
targeting Chk1 was purchased from Sigma-Aldrich. They were provided 
as ready-to-use lentiviral particles. The shRNA corresponding sequences 
are given in Supplemental Table 3. Neurosphere-derived progenitors were 
transduced by lentiviral particles according to manufacturer recommenda-
tions as described in Supplemental Methods.
Statistics. Quantitative data are expressed as mean ± SEM for each treat-
ment group. Results were compared using Student’s t tests (2-tailed) or 
ANOVA with Bonferroni’s multiple comparison of means test (GraphPad 
Prism; GraphPad Software). P < 0.05 was considered significant.
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